糖蛋白 VI (GPVI) 是一种血小板特有的膜糖蛋白,已被确定为胶原蛋白的生理受体。血管壁受损会使内皮下成分胶原蛋白暴露于血流中的血小板。血小板通过受体 GPVI 与胶原蛋白相互作用,导致血小板活化和粘附——这些过程对于血栓形成至关重要。在血小板表面,GPVI 与同型二聚体 Fc 受体 y 链(FcRgamma 可能具有两个 GPVI 分子和一个 FcRgamma 二聚体的化学计量)形成复合物。当胶原蛋白与 GPVI 结合时,血小板活化级联由 FcRgamma 的免疫受体酪氨酸活化基序的酪氨酸磷酸化引发,这种磷酸化诱导由许多信号转导蛋白组成的大型复合物的形成。在与生理条件非常接近的流动粘附实验中,GPVI 对于胶原蛋白上大型血小板聚集体的形成至关重要。
Glycoprotein VI (GPVI) is a membrane glycoprotein unique to platelets and has been identified as a physiological receptor for collagen. Damage to a vessel wall exposes the subendothelial component collagen to platelets in the blood flow. Interaction of platelets with collagen via the receptor GPVI results in platelet activation and adhesion--the processes that are essential for thrombus formation. On the platelet surface, GPVI is present as a complex with the homodimeric Fc receptor y-chain (FcRgamma with a possible stoichiometry of two GPVI molecules and one FcRgamma dimer). When collagen binds to GPVI, a platelet activation cascade is initiated by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of FcRgamma and this phosphorylation induces the formation of a large complex composed from many signal-transducing proteins. In flow adhesion experiments that closely approximate physiological conditions, GPVI is essential for the formation of large platelet aggregates on collagen.
10P3Me 是一种靶向 Glypican-3 (GPC3) 的探针,与人源靶点的 Ka 为 93.8 nM,对 GPC3 具有高结合亲和力,能够靶向 GPC3 阳性细胞并用于 PET 成像,且在包括皮下异种移植模型和原位 HepG2-LUC 肝癌模型在内的 GPC3 阳性肿瘤组织中选择性聚集,从而实现病灶的精确定位。
DOTA-GPC3 targeting peptide 2(Sequence 30)是一种靶向 GPC3 的 RDC 肽,Kd 为 0.3 nM,由 DOTA 和 GPC3 targeting peptide 2 组成,并可被放射性元素标记。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号